Investors Sell Pfizer (PFE) on Strength (PFE)

Investors sold shares of Pfizer Inc. (NYSE:PFE) on strength during trading hours on Monday. $88.20 million flowed into the stock on the tick-up and $190.63 million flowed out of the stock on the tick-down, for a money net flow of $102.43 million out of the stock. Of all equities tracked, Pfizer had the 11th highest net out-flow for the day. Pfizer traded up $0.55 for the day and closed at $36.26

Several equities research analysts have recently weighed in on the stock. Jefferies Group set a $39.00 target price on shares of Pfizer and gave the company a “neutral” rating in a research note on Thursday, November 16th. JPMorgan Chase & Co. set a $39.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Wednesday, November 1st. Nord/LB reissued a “neutral” rating on shares of Pfizer in a research note on Tuesday, January 2nd. Morgan Stanley set a $41.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Friday, January 5th. Finally, Berenberg Bank set a $36.00 target price on shares of Pfizer and gave the company a “neutral” rating in a research note on Tuesday, October 31st. Two analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $39.45.

The stock has a market cap of $216,140.00, a P/E ratio of 10.30, a P/E/G ratio of 2.05 and a beta of 0.94. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.56 by $0.06. The company had revenue of $13.70 billion for the quarter, compared to the consensus estimate of $13.67 billion. Pfizer had a net margin of 40.55% and a return on equity of 26.86%. The firm’s revenue was up .6% compared to the same quarter last year. During the same quarter last year, the firm posted $0.47 EPS. sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 1st. Investors of record on Friday, February 2nd will be paid a $0.34 dividend. This represents a $1.36 annualized dividend and a yield of 3.75%. The ex-dividend date is Thursday, February 1st. This is an increase from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s dividend payout ratio (DPR) is currently 38.64%.

Pfizer declared that its board has approved a stock buyback program on Monday, December 18th that authorizes the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization authorizes the biopharmaceutical company to reacquire shares of its stock through open market purchases. Shares repurchase programs are often a sign that the company’s board of directors believes its stock is undervalued.

In other Pfizer news, EVP Rady A. Johnson sold 8,000 shares of the stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $37.07, for a total transaction of $296,560.00. Following the transaction, the executive vice president now directly owns 46,963 shares in the company, valued at approximately $1,740,918.41. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Alexander R. Mackenzie sold 6,750 shares of the stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $37.00, for a total transaction of $249,750.00. Following the transaction, the insider now owns 103,458 shares in the company, valued at $3,827,946. The disclosure for this sale can be found here. 0.06% of the stock is owned by corporate insiders.

Institutional investors have recently modified their holdings of the business. Peregrine Asset Advisers Inc. boosted its holdings in shares of Pfizer by 0.5% in the 2nd quarter. Peregrine Asset Advisers Inc. now owns 7,354 shares of the biopharmaceutical company’s stock valued at $247,000 after buying an additional 35 shares in the last quarter. Northwest Quadrant Wealth Management LLC boosted its holdings in shares of Pfizer by 0.8% in the 2nd quarter. Northwest Quadrant Wealth Management LLC now owns 6,329 shares of the biopharmaceutical company’s stock valued at $211,000 after buying an additional 50 shares in the last quarter. River Wealth Advisors LLC boosted its holdings in shares of Pfizer by 0.3% in the 2nd quarter. River Wealth Advisors LLC now owns 15,818 shares of the biopharmaceutical company’s stock valued at $531,000 after buying an additional 55 shares in the last quarter. Stone House Investment Management LLC boosted its holdings in shares of Pfizer by 1.0% in the 2nd quarter. Stone House Investment Management LLC now owns 7,236 shares of the biopharmaceutical company’s stock valued at $243,000 after buying an additional 72 shares in the last quarter. Finally, Highland Private Wealth Management boosted its holdings in shares of Pfizer by 0.8% in the 2nd quarter. Highland Private Wealth Management now owns 9,047 shares of the biopharmaceutical company’s stock valued at $304,000 after buying an additional 76 shares in the last quarter. Institutional investors own 70.12% of the company’s stock.

TRADEMARK VIOLATION WARNING: This news story was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international trademark and copyright law. The legal version of this news story can be accessed at https://ledgergazette.com/2018/02/19/investors-sell-pfizer-pfe-on-strength-pfe.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply